10-Q: ASP Isotopes Reports Q3 Loss Amid Strategic Acquisitions & QLE IPO Push

ASP Isotopes Inc. reported a significant net loss for Q3 2025, primarily due to non-cash fair value adjustments, while advancing strategic acquisitions and its Quantum Leap Energy spin-off plans.

Summary

• Net loss attributable to ASP Isotopes Inc. shareholders for the nine months ended September 30, 2025, was $96.38 million, a substantial increase from $25.93 million in the prior year.
• Total revenue for the nine months ended September 30, 2025, increased to $7.19 million from $2.95 million in 2024, driven by the acquisition of Skyline Builders Group Holding Ltd. and continued product revenue from PET Labs.
• Operating expenses rose significantly, with Research and Development at $5.51 million (up from $1.72 million) and Selling, General and Administrative at $30.70 million (up from $17.98 million) for the nine months ended September 30, 2025.
• Cash and cash equivalents stood at $113.94 million as of September 30, 2025, up from $61.89 million at December 31, 2024, bolstered by recent capital raises.
• The company commenced commercial production of enriched isotopes at two ASP enrichment facilities in South Africa during the first half of 2025.
• Anticipated shipments include enriched C-12 in Q4 2025, Si-28 in Q1 2026, and C-14 in H1 2026.
• Commercial samples of highly enriched Yb-176 are being produced, with commercial quantities expected in H1 2026.
• QLE confidentially submitted a draft registration statement on Form S-1 to the SEC in November 2025 for its proposed initial public offering.
• QLE acquired a 79% controlling interest in Skyline Builders Group Holding Ltd. in August 2025, adding construction services in Hong Kong to its operations.
• ASP Isotopes purchased 2,000,000 shares of IsoBio, Inc. Series Seed-1 Preferred Stock for $5.0 million in July 2025.
• The company acquired East Coast Nuclear Pharmacy, LLC (ECNP) in October 2025 for $2.5 million.
• QLE acquired assets from One 30 Seven Inc. in October 2025, focusing on nuclear waste decontamination solutions, with potential future payments up to $17.0 million.
• A $30.0 million bridge loan to Renergen Limited, related to a proposed acquisition, had its repayment date extended to November 28, 2025.
• QLE entered into a Loan Agreement with TerraPower for up to $22.0 million to partially fund a new uranium enrichment facility in South Africa, with two HALEU supply agreements in place for 2028-2037.

Sentiment

Score: 4

Explanation: While the company has made significant strategic moves and raised substantial capital, the reported net loss is very high, primarily due to non-cash fair value adjustments, and operating cash burn has increased. The material weakness in internal controls and ongoing legal proceedings are notable concerns. The positive strategic developments are offset by the financial performance and execution risks.

Positives

• Successfully raised significant capital, including $46.8 million in June 2025, $56.3 million in July 2025, and $199.7 million in October 2025 through common stock offerings.
• QLE secured $72.2 million in gross proceeds from convertible promissory notes in November 2025, including $30.0 million from ASP Isotopes and $10.0 million from a related party.
• Commenced commercial production of enriched isotopes at two ASP facilities in South Africa during the first half of 2025.
• Progressing towards commercial shipments of C-12 (Q4 2025), Si-28 (Q1 2026), C-14 (H1 2026), and Yb-176 (H1 2026).
• Strategic acquisitions of Skyline Builders Group Holding Ltd., IsoBio, Inc., East Coast Nuclear Pharmacy, LLC, and assets from One 30 Seven Inc. expand business scope and market reach.
• Secured a loan agreement with TerraPower for up to $22.0 million to fund a uranium enrichment facility and established long-term HALEU supply agreements.
• QLE confidentially submitted a draft S-1 registration statement for its proposed initial public offering, indicating progress towards the planned spin-off.

Negatives

• Reported a significant net loss of $96.38 million for the nine months ended September 30, 2025, a substantial increase from $25.93 million in the prior year, primarily due to a $64.54 million change in fair value of convertible notes payable.
• Operating expenses increased substantially, with R&D up 219.7% and SG&A up 70.8% for the nine months ended September 30, 2025.
• Net cash used in operating activities increased to $19.93 million for the nine months ended September 30, 2025, from $12.94 million in the prior year.
• A material weakness in internal control over financial reporting was identified, requiring remediation efforts.
• An ongoing putative securities class action lawsuit alleges misleading statements and omissions, posing a legal and financial risk.

Risks

• Ability to achieve or sustain positive cash flows from operations or profitability.
• Challenges in completing construction, commissioning, and successfully operating isotope enrichment plants in a cost-effective manner.
• Difficulty in meeting and continuing to meet applicable regulatory requirements for isotope use and obtaining regulatory approvals for uranium enrichment.
• Uncertainty in executing various projects and strategic initiatives with potential customers and partners, including uranium enrichment in South Africa.
• Potential failure of demand for various isotopes produced using ASP or Quantum Enrichment technology.
• Future capital requirements and the ability to obtain funding for operations and future growth on acceptable terms.
• Extensive costs, time, and uncertainty associated with new technology development.
• Inability to implement and maintain effective internal controls, as a material weakness has been identified.
• Problems with the performance of the ASP technology or the Quantum Enrichment technology in isotope enrichment.
• Dependence on a limited number of third-party suppliers for certain components and a limited number of key customers for isotopes.
• Inability to adapt to changing technology and diagnostic landscapes, such as new diagnostic scanners or tracers.
• Inability to protect intellectual property and the risk of claims of infringement on others' intellectual property.
• Inability to compete effectively in the market.
• Risks associated with the current economic environment, international operations, credit counterparty risks, geopolitical risks, and changes in applicable laws or regulations.
• Inability to adequately protect technology infrastructure.
• Challenges in hiring or retaining skilled employees and the potential loss of key personnel.
• Operational risks inherent in the business.
• Costs and other risks associated with being a reporting company and subject to the Sarbanes-Oxley Act.
• Inability to complete the Renergen acquisition within the anticipated timeframe or at all, due to unfulfilled closing conditions (regulatory approvals, third-party consents) by November 28, 2025.
• Inability to be repaid the $30.0 million advanced to Renergen under the loan agreement if the acquisition is unsuccessful.
• Inability to negotiate a favorable term sheet for a potential $30.0 million debt financing to neutralize the Renergen transaction's effect on cash position.
• Risks associated with QLE's investment in Skyline, including exposure to the civil engineering services operations in Hong Kong, a new market for the company.
• Acquisitions and investments may be unsuccessful, consume significant resources, divert management's attention, lead to integration difficulties, loss of key personnel/customers, or unforeseen liabilities.

Future Outlook

The company expects its current cash and cash equivalents, along with recent capital raises, to fund operations for more than 12 months. It anticipates needing to raise additional capital beyond the next year. The board intends to pursue the separation of its Nuclear Fuels (QLE) and Specialist Isotopes businesses into two independent public companies, with QLE aiming to initiate its IPO process during Q4 2025, subject to market conditions and approvals. Commercial shipments of enriched C-12 are expected in Q4 2025, Si-28 in Q1 2026, C-14 in H1 2026, and Yb-176 in H1 2026. Construction of the uranium enrichment facility with TerraPower is expected to begin in early 2026, with HALEU supply commencing in 2028.

Management Comments

• The board of directors intends to pursue the separation of our Nuclear Fuels business and Specialist Isotopes and Related Services business in two independent companies.
• We believe that both companies would benefit if QLE is independently managed and financed.
• We are aiming to initiate the process for listing of QLE as a separate public company during the fourth quarter of 2025, subject to market conditions and obtaining applicable approvals and consents and complying with applicable rules and regulations and public market trading and listing requirements.
• Our board of directors remains committed to maximizing shareholder value creation, and will continue to evaluate other options for separation to maximize shareholder value.
• The Company does not plan to request drawdown on this loan (TerraPower) until early 2026 when construction of the uranium enrichment facility is expected to begin.
• Defendants intend to vigorously defend against the Securities Class Action.

Industry Context

ASP Isotopes is operating in the high-growth and strategically important sectors of advanced materials, nuclear fuels, and radiopharmaceuticals. The planned spin-off of Quantum Leap Energy (QLE) into a standalone nuclear fuels company aligns with a broader industry trend of specialization to unlock value, particularly given the distinct regulatory and supply chain landscapes for nuclear fuel versus medical isotopes. The focus on High-Assay Low-Enriched Uranium (HALEU) positions QLE to capitalize on the emerging market for small modular reactors. Acquisitions like IsoBio and ECNP strengthen the company's position in the radiotherapeutic and nuclear medicine distribution markets, which are experiencing growth due to advancements in diagnostic and therapeutic applications. The acquisition of One 30 Seven Inc. also positions QLE in the critical area of nuclear waste decontamination, addressing a significant environmental and operational challenge in the nuclear industry. The investment in Skyline, a civil engineering firm, represents a diversification into critical materials supply chain, potentially securing feedstocks vital for the company's long-term growth and national security interests.

Management Changes

Corporate Governance

Legal Proceedings

• A putative securities class action lawsuit (Corredor v. ASP Isotopes Inc., et al.) was filed on December 4, 2024, alleging materially misleading or false statements/omissions by ASP Isotopes Inc. and certain executive officers between October 30, 2024, and November 26, 2024. The complaint seeks unspecified compensatory damages, attorneys' fees, and costs. Defendants intend to vigorously defend against the action.

Related Party Transactions

• QLE received $10.0 million in gross proceeds from American Ventures LLC, Series IX Quantum Leap, a related party, for convertible notes in November 2025.
• QLE received $30.0 million in gross proceeds from ASP Isotopes, its parent company, for convertible notes in November 2025.
• QLE entered into an Advisory Agreement with American Ventures LLC, a related party, in October 2025, issuing RSUs representing 4.0% of QLE's common equity, vesting upon a listing event.
• Skyline, a 79% controlled subsidiary of QLE, has transactions with Ngo Chiu Lam (Director of Skyline) and entities controlled by him (Kin Chiu Development Company Limited, Kin Chiu-China Railway First Group Joint Venture, Kin Chiu-Glory Joint Venture, Kin Chiu-Geotech Joint Venture). Due to related parties totaled $3,438,275 as of September 30, 2025.
• PET Labs has an operating lease for office and production space in Pretoria, South Africa, with the sole owner of the facility being Dr. Gerdus Kemp, an officer of PET Labs and an employee of ASP UK.

Stakeholder Impact

• **Shareholders**: Potential dilution from recent and future equity raises. Significant net losses and increased operating expenses may concern investors, but strategic acquisitions and the QLE spin-off could unlock future value. The securities class action lawsuit poses a risk.
• **Employees**: Increased headcount and salaries contribute to higher personnel-related costs. The 2025 Inducement Equity Incentive Plan is designed to attract new hires, particularly from Renergen, if the acquisition is completed.
• **Customers**: Continued development and commercialization of isotopes (C-12, Si-28, C-14, Yb-176) aim to provide new products. The TerraPower supply agreements secure long-term HALEU supply for nuclear fuel customers. Acquisitions like ECNP expand radiopharmaceutical distribution.
• **Suppliers**: Dependence on a limited number of third-party suppliers for certain components poses a risk.
• **Creditors**: The extension of the Renergen bridge loan repayment date and the negotiation of new debt financing indicate ongoing capital management activities that could affect creditors. Convertible notes and other debt obligations are significant.

Next Steps

• Ship the first commercial batch of enriched C-12 during the fourth quarter of 2025.
• Initiate the process for listing Quantum Leap Energy (QLE) as a separate public company during the fourth quarter of 2025, subject to market conditions and approvals.
• Ship the first commercial batch of enriched Si-28 during the first quarter of 2026.
• Ship the first commercial batch of enriched C-14 in the first half of 2026.
• Ship commercial quantities of Yb-176 during the first half of 2026.
• Begin construction of the uranium enrichment facility in South Africa in early 2026.
• Finalize the purchase price allocation for the Skyline acquisition within 12 months from the acquisition date (August 29, 2025).
• Remediate the material weakness in internal control over financial reporting by enhancing formal documentation and hiring additional accounting, finance, and IT resources.
• Continue to vigorously defend against the securities class action lawsuit.
• Complete the Renergen acquisition by November 28, 2025, subject to fulfilling or waiving closing conditions, including regulatory and debtor approvals.
• Negotiate a favorable term sheet with institutional debt investors for a potential $30 million debt financing to neutralize the effect of the Renergen transaction on the company's cash position.

Key Dates

Recommendation

ASP Isotopes Inc. presents a mixed financial picture. While the company has successfully executed multiple capital raises, significantly increasing its cash position, and is actively pursuing strategic acquisitions and a spin-off of its nuclear fuels business (QLE), the reported net loss for the nine months ended September 30, 2025, is substantial, largely driven by non-cash fair value adjustments on convertible notes. Operating expenses have also risen sharply, indicating increased cash burn. The identified material weakness in internal controls and the ongoing securities class action lawsuit are notable governance and legal risks. The strategic initiatives, particularly in isotope production and the HALEU market, offer long-term growth potential, but these are still in early commercialization or development phases with inherent execution risks. Given the significant capital infusion and strategic progress, but also the substantial losses and operational challenges, a 'hold' recommendation is appropriate. Investors should monitor the QLE spin-off, Renergen acquisition, and the company's ability to achieve profitability and resolve internal control issues.

Keywords

Isotope Enrichment, Nuclear Fuels, Radiopharmaceuticals, Quantum Enrichment, ASP Technology, HALEU, Uranium-235, Carbon-14, Silicon-28, Ytterbium-176, Medical Isotopes, Critical Materials, SEC Filing, 10-Q, Acquisitions, Spin-off, Capital Raise, Renergen, TerraPower, Skyline Builders, IsoBio, One 30 Seven, PET Labs